作者: Krzysztof J. Grzegorzewski , Blake Tomkinson , Marie-Laure Ozoux , Antoine Deslandes
DOI:
关键词:
摘要: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction apoptosis, antibody-dependent cell- mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. disclosed may be used as medicament or in the making medicament, wherein to administered human subject safe therapeutic dose about 20 mg/kg below. In one embodiment, for treating multiple Myeloma humans.